ArticleFuture oncology (London, England)2025

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.

Gregory M Cote et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.